Programme

Acrobat Icon Download Programme (pdf) (3.4mb)

Posters >>

Monday 7 April
09.00 onwards   Registration
Main Foyer
10.30 12.30  Bone and Mineral Special Interest Group Satellite: Osteoporosis
In association with the National Osteoporosis Society
Generously supported by Novartis & Roche
Queen's Suite 2
Chairs: J Wass (Oxford) & R Eastell (Sheffield)
10.30Reception
   
11.00Chairman's introduction: osteoporosis - the silent epidemic?
J Wass (Oxford) & R Eastell (Sheffield)
   
11.10NICE ways to manage osteoporosis
P Selby (Manchester)
   
11.30'But doctor I can't take generic alendronic acid!'
R Eastell (Sheffield)
   
11.50'But doctor no guidelines apply to my situation'
S Orme (Leeds)
   
12.10So you want to set up an osteoporosis service?
A McLellan (Glasgow)
   
10.30 12.30  Andrology Special Interest Group Satellite: Controversies in the diagnosis and management of hypogonadism
Generously supported by Bayer Schering Pharma & ProStrakan
Queen's Suite 1
Chair: H Jones (Sheffield)
10.30Hypogonadism and diabetes
H Jones (Sheffield)
   
10.50Aging, frailty and testosterone
F Wu (Manchester)
   
11.10Difficulties in the diagnosis of hypogonadism
S Arver (Stockholm, Sweden)
   
11.30Testosterone and prostate safety
M Feneley (London)
   
11.50Discussion
   
12.30 13.00  Lunch
Hall Q
13:00 15:00   Symposium 1: New twists in appetite/satiety signalling pathways
King's Suite
Chairs: S O'Rahilly (Cambridge) & K Smith (London)
13.00S9Plasma triglycerides and appetite control
W Banks (St Louis, USA)
   
13.30S10Imaging the brain appetite network
S Luckman (Manchester)
   
14.00S11Role of central serotonin 2C receptors in appetite control
L Heisler (Cambridge)
   
14.30S12Central role of AMP-Kinase in appetite control
M Korbonits (London)
   
13:00 15:00  Clinical Management Workshop 1: Fibrous dysplasia and McCune-Albright syndrome
Supported by Clinical Endocrinology
Main Auditorium
Chairs: R Thakker (Oxford) & M Cooper (Birmingham)
13.00S44The endocrine consequences of McCune-Albright syndrome
P Trainer (Manchester)
   
13.40S45Molecular genetics and cell biology of McCune-Albright syndrome and fibrous dysplasia
L Weinstein (Bethesda, USA)
   
14.20S46Medical treatment of fibrous dysplasia of bone
R Chapurlat (Lyon, France)
   
13:00 15:00  Molecular Endocrinology Workshop
Queen's Suite 1
Chairs: M Gurnell (Cambridge) & K Boelaert (Birmingham)
13.00S70Cell metabolomics: differential metabolism of glucose and fructose in pancreatic cancer
T Heaney (Los Angeles, USA)
   
14.00S71Combining mouse genetics, transgenics and knockouts to explore the biology of MC1R aganism and antagonism
I Jackson (Edinburgh)
   
15:00 15:30  Coffee
Hall Q
15:30 17:30  Symposium 2: System-specific effect steroids
King's Suite
Chairs: S Lightman (Bristol) & G Lavery (Birmingham)
15.30S13Glucocorticoid signalling in the brain
S Lightman (Bristol)
   
16.00S14Glucocorticoids, 11beta HSDs and neuroprotection
M Holmes (Edinburgh)
   
16.30S15Glucocorticoids, liver, fat and metabolic syndrome
P Stewart (Birmngham)
   
17.00S16Glucocorticoids, folliculo-stellate cells and the pituitary
H Christian (Oxford)
   
15:30 17:30  Oral Communications 1: Young Endocrinologists Prize Session
Main Auditorium
Chairs: J Wass (Oxford) & A McNeilly (Edinburgh)
15.30OC1Clinical manifestations of familial paraganglioma and phaeochromocytomas in succinate dehydrogenase B gene mutation carriers
   
15.45OC2The ghrelin-cannabinoid axis – a novel pathway in the regulation of appetite and metabolism
   
16.00OC3Does 11beta-HSD1 in visceral adipose tissue (VAT) deliver cortisol to the liver? Studies with portal vein sampling and tracer infusion in humans.
   
16.15OC4Hypoxia and GC signalling regulate macrophage migration inhibitory factor (MIF) gene expression through a common element
   
16.30OC5Placental vascular development and nutrient transport in 11ß-HSD2-/-mice
   
16.45OC6MRAP2 permits the functional expression of the melanocortin-2-receptor: a new member of a new family of melanocortin receptor accessory proteins
   
17.00OC7Testosterone treatment improves muscle strength, lean mass and quality of life in prefrail and frail elderly men: Results from a randomised double-blind placebo-controlled study
   
17.15OC8β-cell 11β-Hydroxysteroid dehydrogenase type 1 contributes to Type 2 Diabetes.
   
15:30 17:30  Oral Communications 2: Reproduction
Queen's Suite 1
Chairs: H Critchley (Edinburgh) & J Prague (London)
15.30OC9Dynamic responses of oestrogen receptors revealed by fluorescent recovery after photobleaching (FRAP)
   
15.45OC10Expression of somatostatin receptors 1-5 in normal human endometrium through the menstrual cycle
   
16.00OC11Identification of a novel compound heterozygous mutation in the gonadotrophin releasing hormone receptor in two siblings with isolated hypogonadotrophic hypogonadism
   
16.15OC12Modelling Kallmann's Syndrome in the zebrafish
   
16.30OC13Effect of hypoxia and inflammatory and anti-inflammatory signals on gene expression in sheep ovarian surface epithelium (OSE) in vitro.
   
16.45OC14IGF-mediated cell turnover in the human placenta is positively regulated by the protein tyrosine phosphatase, SHP-2.
   
17.00OC15Evaluation of the prevalence of vitamin D deficiency and its treatment in a west London pregnant population
   
17.15OC16Enhanced hypothalamic-pituitary-adrenal axis activation, 5α-reductase activity and insulin resistance distinguishes polycystic ovary syndrome from simple obesity
   
17:30 17:45  Tea
Hall Q
17:45 18:45  Young Endocrinologist Prize Lectures
Main Auditorium
Chairs: P Stewart (Birmingham) & A McNeilly (Edinburgh)
17.45S64Peptide YY: Food for thought
R Batterham (London)
   
18.15S6511b-HSD1 and metabolic disease: a mouses’ Tail
N Morton (Edinburgh)
   
18:45 onwards   Welcome Reception
Holiday Inn
19:45 onwards   Young endocrinologists quiz night
Generously supported by Fisher Scientific & Novo Nordisk Ltd
Hall D
Tuesday 8 April
07:15 08:00  Clinical Expert 1: Management of prolactinoma
Supported by Clinical Endocrinology
Queen's Suite 1
Chair: R Murray (Leeds)
J Bevan (Aberdeen)
07:15 08:00  Clinical Expert 2: Clinical management of MEN 1 or 2
Supported by Clinical Endocrinology
Queen's Suite 2
Chair: J Davis (Manchester)
R Thakker (Oxford)
08:15 10:15  Symposium 3: Hypoxia: its effects on physiology and pathophysiology
Queen's Suite 2
Chairs: M Westwood (Manchester) & K Forbes (Manchester)
08.15S17Hypoxia signalling and VHL
P Maxwell (London)
   
08.45S18Prenatal hypoxia and early origins of heart disease
D Giussani (Cambridge)
   
09.15S19Hypoxia, angiogenesis and proliferative diabetic retinopathy
P Bishop (Manchester)
   
09.45S20Understanding VEGF Action: the role of a novel factor, Dll4
S Wiegand (Regeneron Pharmaceuticals)
   
08:15 10:15  Oral Communications 3: Bone, Diabetes and Tumours
Queen's Suite 1
Chairs: R Rosenfeld (Palo Alto, USA) & A Swali (Birmingham)
08.15OC17Cinacalcet is an effective and well tolerated treatment for MEN1 associated primary hyperparathyroidism
AMEND YOUNG INVESTIGATOR AWARD WINNER
   
08.30OC18Human omental adipose tissue as a key site for the inflammatory 15-lipoxygenase pathway: Implications for metabolic disease.
   
08.45OC19Expression of the parathyroid-specific transcription factor glial cell-Missing B (GCMB) is regulated by GATA3
   
09.00OC20Serum 18 hydroxycortisol identifies aldosteronoma in the differential diagnosis of primary aldosteronism
   
09.15OC21Delineating the mechanisms of visfatin regulation in human AT and the implications of TZD treatment in type 2 diabetes
   
09.30OC22Cataracts are a phenotypic feature of autosomal dominant hypocalcaemia with hypercalciuria (ADHH): lessons from the Nuf mouse model with an activating calcium sensing receptor (CaSR) mutation
   
09.45OC23Obesity resulting from Gs-alpha mutations in the maternal (but not paternal) allele is a consequence of Gs-alpha imprinting in the central nervous system
   
10.00OC24The calcilytic agent NPS2143 rectifies hypocalcaemia in a mouse model, Nuf, that is due to an activating calcium-sensing-receptor (CaSR) mutation: Relevance to Autosomal Dominant Hypocalcaemia with Hypercalciuria
NOVARTIS AWARD WINNER
   
08:15 10:15  Clinical Management Workshop 2 - PCOS: Impact on long term health outcomes
Supported by Clinical Endocrinology
Main Auditorium
Chairs: J Ahlquist (Southend) & T Sathyapal (Hull)
08.15S47Fat metabolism, obesity, NASH in PCOS and insulin resistant states
S Atkin (Hull)
   
08.55S48Cardiovascular implications of PCOS
F Orio (Naples, Italy)
   
09.35S49Long-term implications of PCOS in children and adolescents
K Ong (Cambridge)
   
10:15 10:40  Coffee
Hall Q
10:40 11:25  Society for Endocrinology Dale Medal Lecture
Main Auditorium
Chair: J Wass (Oxford)
S1Hormones and ovaries: a lifelong journey
A McNeilly (Edinburgh)
   
11:25 11:55  Society for Endocrinology Transatlantic Medal Lecture
Main Auditorium
Chair: J Wass (Oxford)
S2Insulin-like growth factors and the evolution of human growth
R Rosenfeld (Palo Alto, USA)
   
12:00 13:30  Lunch
Hall Q
12:15 13.00  Attended posters
Hall Q
13:30 15:30  Symposium 4: Thyroid hormones in development: physiology and clinical implications
Main Auditorium
Chairs: S Cheng (Bethesda, USA) & D Bassett (London)
13.30S21Thyroid Hormone Transport and Neurological Development
T Visser (Rotterdam, The Netherlands)
   
14.00S22New roles of deiodinases in development
A Bianco (Boston, USA)
   
14.30S23The HPT axis in control of skeletal development
G Williams (London)
   
15.00S24Clinical implications of fetal and neonatal thyroid development
R Hume (Dundee)
   
13:30 15:30  Oral Communications 4: Pituitary and steriods
Queen's Suite 1
Chairs: J Connell (Glasgow) & O Evuarherhe (Bristol)
13.30OC25Identification of MC2R receptor accessory protein domains required for interaction with MC2R and formation of a functional ACTH responsive receptor
   
13.45OC26A role for CD38 in anterior pituitary somatotrophs? Studies in CD38 null mice
   
14.00OC27Adipose GR knockdown protects against obesity in female mice
   
14.15OC28Pre-receptor cortisol metabolism is a critical regulator of insulin signalling in human adipose tissue
   
14.30OC29Targeting Cyp11b1 expression in mice to model sequelae of congenital adrenal hyperplasia
   
14.45OC30Local cortisol generation by human macrophage subsets by 11beta-hydroxysteroid dehydrogenase type 1 enzyme and its role in ocular immune privilege
   
15.00OC31Do polyunsaturated fatty acids stimulate steroidogenesis through expression of liver x receptor?
   
15.15OC32Coupling of GR cellular distribution and function to the cell cycle
   
13:30 15:30  Young Endocrinologist Session: Obtaining funding for Young Endocrinologists
Queen's Suite 2
Chairs: K Jonas (London) & A Munir (Sheffield)
13.30S66Funding for research fellowships
T Skerry (Sheffield)
   
14.00S67Clinical Research Fellowships: an insider’s account
F Swords (London)
   
14.30S68Basic science research lectureships: a day in the life of ...
M Westwood (Manchester)
   
15.00S69The 'been-to-America' degree revisited: is it really still worth it?
R Fowkes (London)
   
15:30 16:00  Tea
Hall Q
16:00 18:00  Clinical Debate: This house believes that males become menopausal
Supported by Clinical Endocrinology
Main Auditorium
Chair: F Wu (Manchester)
D1For
P Bouloux (London)
   
D2Against
A Andersson (Copenhagen, Denmark)
   
16:00 18:00  Oral Communications 5: Thyroid
Queen's Suite 1
Chairs: S Cheng (Bethesda, USA) & P Beck-Peccoz (Milan, Italy)
16.00OC33Effect of thyroid status on the skeleton in post-menopausal women: the OPUS study
NOVARTIS AWARD WINNER
   
16.15OC34Maternal isodisomy for a novel human FOXE1 gene mutation in syndromic congenital hypothyroidism
   
16.30OC35Circulating endothelial progenitor cells are reduced in subclinical and overt hypothyroidism
   
16.45OC36Increased skeletal mineralisation in mice lacking type 2 iodothyronine deiodinase
   
17.00OC37Endocytosis involves a CLC-5 and KIF3B Interaction: relevance to thyroid and renal tubular function.
   
17.15OC38Serious vascular events for patients on long-term thyroxine: the TEARS Study
   
17.30OC39HIF-1α is a common downstream target of PI3K and MAPK/ERK signalling in thyroid carcinomas
   
17.45OC40Direct actions of T3 in proliferating chondrocytes regulate endochondral ossification and linear growth
BRITISH THYROID ASSOCIATION AWARD WINNER
   
16:00 18:00  Symposium 5: Androgen receptors – physiology and disease
Queen's Suite 2
Chairs: I McEwan (Aberdeen) & V Bombail (Edinburgh)
16.00S25Tissue-specific androgen receptor knockout models: novel tools in the study of androgen action
G Verhoeven (Leuven, Belgium)
   
16.40S26Loss of androgen receptor bindingto selective androgen response elements causes a reproductive phenotype in transgenic SPARKI mice
F Claessens (Leuven, Belgium)
   
17.20S27Androgen receptors in development: biochemical and clinical correlates
I Hughes (Cambridge)
   
16:00 17:00  Clinical Expert 1 (repeat): Management of prolactinoma
Supported by Clinical Endocrinology
King's Suite
Chair: R Murray (Leeds)
J Bevan (Aberdeen)
17:00 18:00  Clinical Expert 2 (repeat): Clinical management of MEN 1 or 2
Supported by Clinical Endocrinology
King's Suite
Chair: J Davis (Manchester)
R Thakker (Oxford)
19:30 onwards   Society for Endocrinology banquet
Old Swan Hotel
Wednesday 9 April
07:15 08:00  Clinical Expert 3: Peri-operative care of phaeos
Supported by Clinical Endocrinology
Queen's Suite 1
Chair: M Serpell (Glasgow)
M Serpell (Glasgow)
07:15 08:00  Clinical Expert 4: Thyroid disease in pregnancy
Supported by Clinical Endocrinology
Queen's Suite 2
Chair: G Brabant (Manchester)
J Lazarus (Cardiff)
08:10 08:55  Society for Endocrinology Annual General Meeting
Main Auditorium
09:00 11:00  Symposium 6: The endocrinology of critical illness
Main Auditorium
Chairs: P Stewart (Birmingham) & S Ball (Newcastle-upon-Tyne)
09.00S28Critical illness: an overview of the physiological and metabolic changes
S Baudouin (Newcastle-upon-Tyne)
   
09.30S29The glucocorticoid axis in critical illness: cause or effect?
M Cooper (Birmingham)
   
10.00S30Thyroid hormone axis in critical illness
S Ball (Newcastle-upon-Tyne)
   
10.30S31Insulin and blood glucose changes in critical illness
G Van den Berghe (Leuven, Belgium)
   
09:00 11:00  Symposium 7: Evolving endocrine targets for C-type natriuretic peptide (CNP)
Queen's Suite 2
Chairs: C McArdle (Bristol) & K Jonas (London)
09.00S32Emerging Roles for CNP
E Espiner (Christchurch, New Zealand)
   
09.30S33The new biology of pituitary natriuretic peptides: novel signalling from guanylyl cyclase-B (GC-B) receptors
R Fowkes (London)
   
10.00S34New aspects of CNP function
R Middendorff (Giessen, Germany)
   
10.30S35Noval cardiovascular roles for CNP
C Villar (London)
   
09:00 11:00  Nurse session 1: Cushing's Syndrome
Queen's Suite 1
Chairs: A Marland (Oxford) & J MacDonald (Oxford)
09.00S57Overview and diagnosis
J Bevan (Aberdeen)
   
09.30S58Cushing's: the worst case scenario
V Thornton-jones (Oxford)
   
10.00S59A case of cyclical Cushing's Syndrome?
V Kieffer (Leicester)
   
10.30S60Cushing's Syndrome - a success story?
S Cox (Torquay)
   
11:00 11:30  Coffee
Hall Q
11:30 12:05  Society for Endocrinology European Medal Lecture
Main Auditorium
Chair: J Buckingham (London)
S3Testicular dysgenesis syndrome (TDS): clinical and environmental aspects
N Skakkebaek (Copenhagen, Denmark)
   
12:05 12:40  Society for Endocrinology Asia and Oceania Medal Lecture
Main Auditorium
Chair: J Wass (Oxford)
S4Unraveling the metabolic mysteries regulating body composition: new insights into old hormones
K Ho (Sydney, Australia)
   
12:40 14:15  Lunch
Hall Q
13.00 13.45  Attended posters
Hall Q
14:15 16:15  Symposium 8: Inflammation and the adipocyte – integrated pathways that regulate disease risk
Queen's Suite 2
Chairs: K Chapman (Edinburgh) & N Fernandes da Silva (Warwick)
14.15S36Leptin as a proinflammatory cytokine
G Lord (London)
   
14.45S37Nuclear receptors and regulation of inflammatory pathways
B Staels (Lille, France)
   
15.15S38Anti-inflammatory and pro-resolution lipid mediators: lessons for obesity-related inflammation.
D Gilroy (London)
   
15.45S39Adipose tissue and chronic inflammation
S Kumar (Warwick)
   
14:15 16:15  Clinical Mangement Workshop 3: Managing the obese patient
Supported by Clinical Endocrinology
Main Auditorium
Chairs: R Murray (Leeds) & S Aylwin (London)
14.15S50Managing the obese patient: lifestyle intervention and prescriptive exercise
R Andrews (Bristol)
   
14.45S51Obesity management – the role of drugs in the 21st Century
J Wilding (Liverpool)
   
15.15S52New insulins - suck 'em and see!
A Robinson (Bolton)
   
15.45S53Role of bariatric surgery
S Aylwin (London)
   
14:15 16:15  Nurse session 2: Diabetes insipidus
Queen's Suite 1
Chairs: V Kieffer (Leicester) & V Thornton-Jones (Oxford)
14.15S61Overview and how to do a water deprivation test: interpretation of results
J Wass (Oxford)
   
14.55S62Water deprivation test: a ‘real’ case
M O' Connor (Oxford)
   
15.35S63Water deprivation test: a 'red herring' case
J MacDonald (Oxford)
   
16:15 16:45  Tea
Hall Q
16:15 16:45  Nurses Tea
Generously supported by Ipsen Ltd
Conference Suite
16:45 17:05  Awards ceremony
Main Auditorium
Chair: J Wass (Oxford)
17:05 17:40  British Thyroid Association Pitt-Rivers Lecture
Supported by the Clinical Endocrinology Trust
Main Auditorium
Chair: A Weetman (Sheffield)
S5Thyroid hormone receptors, mutations, and cancer development
S Cheng (Bethesda, USA)
   
17:40 18:15  Clinical Endocrinology Visiting Professor Lecture
Supported by the Clinical Endocrinology Trust
Main Auditorium
Chair: A Weetman (Sheffield)
S6Inappropriate secretion of TSH
P Beck-Peccoz (Milan, Italy)
   
18:15 18:45  PCOS satellite reception
A buffet will be sereved for those attending the satellite
Generously supported by Almirall Ltd
Upper foyer
18:15 18:45  Neuroendocrine Tumours Satellite reception
A buffet will be available for those attending the satellite
Generously supported by Novartis
Queen's Suite foyer
18:45 20:45  PCOS and Metabolic Syndrome Special Interest Group Satellite: Advances in PCOS in the last 12 months
Generously supported by Almirall Ltd
Main Auditorium
Chairs: S Atkin (Hull) & H Randeva (Warwick)
18.45An update and highlights of the basic science advances of PCOS
H Randeva (Warwick)
   
19.15An update and highlights of the reproductive aspects of PCOS
A Balen (Leeds)
   
19.45An update and highlights of the cosmetic aspects of PCOS
A Layton (Harrogate)
   
20.15Discussion
   
18:45 20:45  Neuroendocrine Tumours Satellite
Generously supported by Novartis
Queen's Suite 1
Chairs: D O'Shea (Dublin, Ireland) & K Meeran (London)
18.45Clinical case discussions and current clinical trials for neuroendocrine tumours
K Meeran (London) & J Newell-Price (Sheffield)
   
19.15Diagnostic and treatment algorithm for neuroendocrine tumours
D O'Shea (Dublin, Ireland)
   
19.45Mechanisms underlying neuroendocrine tumourigenesis and development of models
R Thakker (Oxford)
   
20.15Tumour targetted radioactive treatment of neuroendocrine tumours
D Kwekkeboom (Rotterdam, The Netherlands)
   
Thursday 10 April
07:15 08:00  Clinical Expert 5: Obesity surgery - who, what and when?
Supported by Clinical Endocrinology
Queen's Suite 1
Chair: R Malik (Manchester)
J Wilding (Liverpool)
07:15 08:00  Clinical Expert 6: Cushing's Syndrome in pregnancy
Supported by Clinical Endocrinology
Queen's Suite 2
Chair: P Trainer (Manchester)
A James (Newcastle-upon-Tyne)
08:15 08:50  Society for Endocrinology Medal Lecture
Main Auditorium
Chair: D Ray (Manchester)
S7The endocrinology of menstruation
H Critchley (Edinburgh)
   
08:55 09:30  Clinical Endocrinology Trust Lecture
Supported by the Clinical Endocrinology Trust
Main Auditorium
Chair: L Rees (London)
S8Aldosterone and cardiovascular function: a lifetime of damage
J Connell (Glasgow)
   
09:30 10:00  Coffee
Hall Q
10:00 12:00  Symposium 9: Recent advances and new treatment options in diabetes
Main Auditorium
Chairs: A Harte (Warwick) & R Davies (Manchester)
10.00S40New approaches to treating diabetic microvascular complications
R Malik (Manchester)
   
10.30S41Incretin-based therapies
C Bailey (Birmingham)
   
11.00S42Immune therapy: prevention is better than cure
B Roep (Leiden, The Netherlands)
   
11.30S43Islet transplantation - way to go!
J Shaw (Newcastle-upon-Tyne)
   
10:00 12:00  Clinical Management Workshop 4: Transitional endocrinology
Supported by Clinical Endocrinology
Queen's Suite 1
Chair: J Davis (Manchester)
10.00S54The management of Prader-Willi syndrome from paediatric to adult care
A Lindgren (Stockholm, Sweden)
   
10.40S55The management of congenital adrenal hyperplasia from paediatric to adult care
P Clayton (Manchester)
   
11.20S56The management of Turner Syndrome from paediatric to adult care
G Conway (London)
   
12:00 12:45  Clinical Expert 3 (repeat): Peri-operative care of phaeos
Supported by Clinical Endocrinology
Queen's Suite 1
Chair: M Serpell (Glasgow)
M Serpell (Glasgow)
12:00 12:45  Clinical Expert 4 (repeat): Thyroid disease in pregnancy
Supported by Clinical Endocrinology
Queen's Suite 2
Chair: G Brabant (Manchester)
J Lazarus (Cardiff)
12:45 13:30  Clinical Expert 5 (repeat): Obesity surgery - who, what and when?
Supported by Clinical Endocrinology
Queen's Suite 1
Chair: R Malik (Manchester)
J Wilding (Liverpool)
12:45 13:30  Clinical Expert 6 (repeat): Cushing's Syndrome in pregnancy
Supported by Clinical Endocrinology
Queen's Suite 2
Chair: P Trainer (Manchester)
A James (Newcastle-upon-Tyne)